Comparative Pharmacology
Head-to-head clinical analysis: BRONKOSOL versus BROVANA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRONKOSOL versus BROVANA.
BRONKOSOL vs BROVANA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bronchodilator via beta-2 adrenergic receptor agonism, increasing intracellular cAMP, leading to smooth muscle relaxation in the airways.
BROVANA (arformoterol tartrate) is a long-acting beta2-adrenergic agonist (LABA). It stimulates intracellular adenyl cyclase, increasing cyclic AMP levels, leading to relaxation of bronchial smooth muscle and inhibition of mast cell mediator release.
2.5 mg (0.5 mL of 0.5% solution) via nebulization three to four times daily, as needed.
15 mcg (2 mL) by nebulization twice daily, not to exceed 30 mcg/day.
None Documented
None Documented
Terminal elimination half-life is 3–4 hours; prolonged in hepatic impairment (up to 8 hours).
Terminal elimination half-life: approximately 26 hours (range 22–30 hours) in healthy adults; prolonged in hepatic impairment (up to 50% increase).
Primarily renal excretion as sulfate conjugates; unchanged drug accounts for <10% of excretion. Biliary/fecal excretion is minimal (<2%).
Primarily renal (60% unchanged drug); remainder via biliary/fecal (approximately 20%) and metabolic transformation.
Category C
Category C
Bronchodilator
Bronchodilator